Thanks to visit codestin.com
Credit goes to jeccr.biomedcentral.com

Skip to main content
BMC is moving to Springer Nature Link. Visit this journal in its new home.

Featured Article: Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling

New Content Item

Plasmacytoid dendritic cells (pDCs) are multifaceted immune cells executing various innate immunological functions. Their first line of defence consists in type I interferons (I-IFN) production upon nucleic acids sensing through endosomal Toll-like receptor (TLR) 7- and 9-dependent signalling pathways. Type I IFNs are a class of proinflammatory cytokines that have context-dependent functions on cancer immunosurveillance and immunoediting. 


In the last few years, different studies have reported that pDCs are also able to sense cytosolic DNA through cGAS–STING (stimulator of interferon genes) pathway eliciting a potent I-IFN production independently of TLR7/9. Human pDCs are also endowed with direct effector functions via the upregulation of TRAIL and production of granzyme B, the latter modulated by cytokines abundant in cancer tissues. pDCs have been detected in a wide variety of human malignant neoplasms, including virus-associated cancers, recruited by chemotactic stimuli. Although the role of pDCs in cancer immune surveillance is still not completely understood, their spontaneous activation has been rarely documented; moreover, their presence in the tumor microenvironment (TME) has been associated with a tolerogenic phenotype induced by immunosuppressive cytokines or oncometabolites. 

This Review integrates recent evidence on the biology of pDCs and their pharmacological modulation, suggesting their relevant role at the forefront of cancer immunity.

Aims and scope

Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.

Please click here to read more.

Editor-in-Chief

Mauro Castelli, Regina Elena National Cancer Institute, Italy

If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to: 

[email protected]

Articles

Springer Nature Oncology Portfolio

Discover the range of academic oncology titles at Springer Nature here.

Call for papers: Breaking cancer DRUG RESISTANCE: Looking for an interdisciplinary effort solving an unmet clinical need in oncology

New Content Item

Journal of Experimental & Clinical Cancer Research is delighted to announce a new thematic series focused on: 

Breaking cancer DRUG RESISTANCE: Looking for an interdisciplinary effort solving an unmet clinical need in oncology

This Collection will accept Research Articles and Reviews in this topic. Submit here

  • Submission opens: 1st May 2025
  • Submission deadline: 30th April 2026

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research. 

Follow JECCR on Social Media

Social Media IconsTwitter

Facebook

LinkedIn

Follow JECCR's social media accounts to be kept up-to-date with the latest articles, collections and journal news!

Recognising Editorial Excellence

SN Editorial Excellence badgeJournal of Experimental & Clinical Cancer Research is a top rated Springer Nature journal. Prof. Mauro Castelli and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.

Reviewer Acknowledgement and New Recruitment

The Editor-in-Chief of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal and is looking for new reviewers to assess manuscripts. For consideration, please send your CV with keywords and expertise to [email protected]

Archival content

Journal of Experimental & Clinical Cancer Research has been publishing since 1982.  Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print.  For enquiries about previous content, please contact us on: 

[email protected]


Annual Journal Metrics

  • Citation Impact 
    Journal Impact Factor: 12.8 (2024)    
    5-year Journal Impact Factor: 12.2 (2024)    
    Source Normalized Impact per Paper (SNIP): 2.009 (2024)    
    SCImago Journal Rank (SJR): 3.328 (2024)

    Speed 
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 96

    Usage 2024
    Downloads: 4,059,655
    Altmetric mentions: 2,197